Adding weightlifting exercises may further reduce risk of mortality
1. After adjusting for aerobic moderate to vigorous physical activity (MVPA), weightlifting was...
Read More
Oncology
Fine needle biopsy remains a reliable test for thyroid cancer diagnosis
1. In this systematic review and meta-analysis that included 16,597 patients, fine needle biopsy...
Read More
Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma
1. Atezolizumab was associated with non-significantly increased disease-free survival compared to...
Read More
Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma
1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab...
Read More
Optimized vitamin C levels may be associated with mitigated HPV infection risk
1. Though not statistically significant, there was a U-shaped found between vitamin C levels and...
Read More
Stereotactic body radiation does not improve outcomes in patients with advanced Merkel cell carcinoma receiving nivolumab and ipilimumab
1. Objective response rate was not significantly different in patients treated with stereotactic...
Read More
Ipilimumab addition to nivolumab showed no significant clinical benefit in resected advanced stage melanoma
Ipilimumab addition to nivolumab showed no significant clinical benefit in resected advanced stage...
Read More
Letrozole and abemaciclib in estrogen receptor–positive recurrent endometrial cancer
1. Almost half of patients (47%) had either an objective response or had progression free survival...
Read More
Fulvestrant for treatment of estrogen receptor-positive, HER2-negative advanced breast cancer may improve progression free survival using ESR1 mutation as guidance
1. Median progression free survival was longer in the fulvestrant and palbociclib group compared...
Read More
Selpercatinib continues to demonstrate effective response in RET fusion-positive NSCLC
1. Selpercatinib was found to have similar effective objective response rates compared to past...
Read More
Selpercatinib showed promising clinical activity in tumour-agnostic patients with RET fusion-positive cancers other than thyroid and lung cancer
1. Objective response rate was 43.9%. Patients treated with selpercatinib also experienced...
Read More
More permissive parameters for active surveillance eligibility is potentially possible in slow-growing thyroid cancers
1. Patients in the active surveillance group who had forgone surgery had no difference in survival...
Read MoreIncreased pre-chemotherapy inflammatory biomarkers (IL-6 and CRP) correlated to increased risk of frailty post-chemotherapy in older breast cancer patients
1. 25.8% of patients receiving chemotherapy for breast cancer experienced worsening frailty status. 2. Patients with both biomarkers (IL-6 and CRP) elevated before chemotherapy had a significantly higher risk of decline in...
Read More
Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients
1. Adjuvant pembrolizumab significantly improved disease-free survival in comparison to placebo in...
Read More
Neoadjuvant celmiplimab is associated with pathologic response in cutaneous squamous cell carcinoma
1. After neoadjuvant treatment with celmiplimab, half of the patients were found to have a...
Read More
Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance
1. Hepatocellular carcinoma (HCC) tumours located in ultrasound (US) blind spots were associated...
Read More
Combination avelumab and axitinib treatment of advanced type B3 thymoma and thymic carcinoma is promising as second-line treatment after standard therapy.
1. Patients who had never previously received anti-angiogenesis treatments had longer...
Read More
Treatment with adjuvant mFOLFIRINOX as compared with gemcitabine improves survival outcomes in resected pancreatic cancer
1. Median disease-free survival is longer in patients receiving mFOLFIRINOX as compared to those...
Read More
Routine dexamethasone is not effective compared to placebo to treat dyspnea in patients with advanced cancer
1. There is no significant difference for perceived dyspnea in patients taking dexamethasone as...
Read More
Telaglenastat addition to cabozantinib did not demonstrate benefit in pre-treated advanced renal cell carcinoma
1. Telaglenastat addition to cabozantinib did not show improvements in clinical benefit. 2....
Read More